Faron Pharmaceuticals Oy
LSE FARN.L
Faron Pharmaceuticals Oy Interest Coverage Ratio for the year ending December 31, 2023
-
Faron Pharmaceuticals Oy Interest Coverage Ratio for the year ending December 31, 2022 was -19.54, a 78.09% change year over year.
-
Faron Pharmaceuticals Oy Interest Coverage Ratio for the year ending December 31, 2021 was -89.20, a -106.73% change year over year.
-
Faron Pharmaceuticals Oy Interest Coverage Ratio for the year ending December 31, 2020 was -43.15, a 25.80% change year over year.
-
Faron Pharmaceuticals Oy Interest Coverage Ratio for the year ending December 31, 2019 was -58.16, a 64.75% change year over year.
| Date | Interest Coverage Ratio | Debt to Equity Ratio | Interest Expense To Sales | Inventory Turnover Ratio |
|---|
Don’t Miss A Beat
| CEO | Dr. Juho Markku Jalkanen M.D., MSc, Ph.D. |
| IPO Date | Nov. 17, 2015 |
| Location | Finland |
| Headquarters | Joukahaisenkatu 6 B |
| Employees | 34 |
| Sector | Healthcare |
| Industries | |
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
Past 5 years
StockViz Staff
February 6, 2025
Any question? Send us an email